A monthly audio round-up detailing the contents of the latest issue of DTB. For 50 years, Drug and Therapeutics Bulletin (DTB) has provided rigorous and independent evaluations of, and practical advice on, individual treatments and the overall management of disease for doctors, pharmacists and other healthcare professionals. DTB has always been wholly independent of the pharmaceutical industry, Government and regulatory authorities. DTB is also free of advertising and other forms of commercial sponsorship. Please subscribe to the DTB podcast to get episodes automatically downloaded to your mobile device and computer. Also, please consider leaving us a review or a comment on the DTB Podcast iTunes podcast page - https://podcasts.apple.com/gb/podcast/dtb-podcast/id307773309. * The purpose of this podcast is to educate and to inform. The content of this podcast does not constitute medical advice and it is not intended to function as a substitute for a healthcare practitioner’s judgement, patient care or treatment. The views expressed by contributors are those of the speakers. BMJ does not endorse any views or recommendations discussed or expressed on this podcast...
https://dtbbmj.podbean.com
Gesamtlänge aller Episoden: 2 days 15 hours 37 minutes
recommended podcasts
episode 165: Drug safety alerts, valproate safety (again) and a new contraceptive POP
In this podcast recorded in early March, James Cave (Editor-in-Chief) and David Phizackerley (Deputy Editor) talk about the April 2024 issue of DTB. They discuss the editorial that questions whether drug safety alerts are effective in changing practi...
episode 164: Protecting consumers, tramadol-warfarin interaction and very low calorie diets
In this podcast recorded in early February, James Cave (Editor-in-Chief) and David Phizackerley (Deputy Editor) talk about the March 2024 issue of DTB. They discuss the editorial highlighting the important work that the founders of The Medical Lett...
episode 163: ADHD medicines shortages, fluoroquinolone safety, drugs not to prescribe
In this podcast recorded in early January, James Cave (Editor-in-Chief) and David Phizackerley (Deputy Editor) talk about the February 2024 issue of DTB. They discuss the editorial that highlights problems associated with shortages of ADHD medicines...
episode 162: Continuity of care, statins and myasthenia gravis, and acne
In this podcast recorded in BMA House in December, James Cave (Editor-in-Chief) and David Phizackerley (Deputy Editor) talk about the January 2024 issue of DTB. They discuss continuity of care in general practice and the benefits it offers (https://d...
episode 161: Rationalising blood tests, bempedoic acid and CV outcomes and semaglutide for obesity
In this podcast, James Cave (Editor-in-Chief) and David Phizackerley (Deputy Editor) talk about the December 2023 issue of DTB. They discuss monitoring drugs in primary care and the need to rationalise the number of blood tests undertaken (https://dt...
episode 160: BNF moving with the times; preventable deaths; plus an intro to pharmacogenetics
In this podcast, James Cave (Editor-in-Chief) and David Phizackerley (Deputy Editor) talk about the November 2023 issue of DTB. They discuss the history of the BNF and the announcement that the 86th edition of the BNF and the 2023–2024 edition of the...
episode 159: Taxing ill health, and what evidence for intravenous vitamins?
In this podcast, James Cave (Editor-in-Chief) and David Phizackerley (Deputy Editor) talk about the October 2023 issue of DTB. They discuss NHS prescription charges in England and the impact they have on people with long-term ill health (https://dtb...
episode 158: NICE and redacted data, spironolactone for acne, and drugs with anticholinergic activity
In this podcast, James Cave (Editor-in-Chief) and David Phizackerley (Deputy Editor) talk about the September 2023 issue of DTB. They discuss concerns over redacted data in NICE appraisal documents (https://dtb.bmj.com/content/61/9/130). They review ...
episode 157: FeNO and asthma, low-dose aspirin and H pylori eradication, plus finerenone
In this podcast, James Cave (Editor-in-Chief) and David Phizackerley (Deputy Editor) talk about the August 2023 issue of DTB. They discuss measurement of fractional exhaled nitric oxide (FeNO) in the management of asthma (https://dtb.bmj.com/content/...
episode 156: July 2023: Whither evidence, COI in guidelines, isotretinoin safety, SGLT2 inhibitors and Utrogestan shortage
In this podcast, James Cave (Editor-in-Chief) and David Phizackerley (Deputy Editor) talk about the July 2023 issue of DTB. They discuss evidence-based medicine, access to evidence and increasing use of press releases and social media to present evid...